National Institutes of Health, a Component of the US Dept. of Health & Human Services

Institute for Research in Biomedicine

Columbia University

Gwo-Yu Chuang

Baoshan Zhang

Tongqing Zhou

Peter D Kwong

Yongping Yang

Ivelin Georgiev

John R Mascola

Guillaume Stewart-Jones

Michael Gordon Joyce

Aliaksandr Druz

Marie Pancera

Jason Gorman

Cheng Cheng

Mark Connors

Wing-Pui Kong

Young Do Kwon

Li Ou

Gilad Ofek

Mallika Sastry

Kai Xu

Jeffrey C Boyington

Gary J Nabel

Antonio Lanzavecchia

Davide Corti

Barney S Graham

Masaru Kanekiyo

Zhi-yong Yang

Jason Scott McLellan

John Mascola

Wei Shi

Xueling Wu

Yaroslav Tsybovsky

Man Chen

Jiang Zhu

Cinque Soto

Rebecca S Rudicell

Lei Chen

Priyamvada Acharya

Rita Chen

Sanjay Srivatsan

Richard Schwartz

Paul Thomas

Lawrence Shapiro

Krisha McKee

Sijy O'Dell

Lisa Kueltzo

Rui Kong

Kevin Liu

Robert Bailer

Mark Louder

Mangaiarkarasi Asokan

Jonathan Cooper

Kevin Carlton

Michael Bender

Amarendra Pegu

Tatyana Gindin

Ulrich Baxa

Rebecca M Lynch

Wing-pui Kong

Yen-Ting Lai

Hui Geng

Jason S Mclellan

Ivelin Stefanov Georgiev

Rebecca Lynch

Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

HIV-1 ENV fusion peptide immunogens and their use

Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Prefusion PIV F immunogens and their use

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Recombinant HIV-1 envelope proteins and their use

Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Prefusion RSV F proteins and their use

HIV-1 Env fusion peptide immunogens and their use

Neutralizing antibodies to HIV-1 GP41 and their use

Immunogens comprising a recombinant HIV-1 Env ectodomain trimer stabilized in a prefusion closed conformation and methods of their use and production are disclosed. In several embodiments, the immunogen can be used to elicit an immune response to HIV-1 in a subject.

Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.

Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein

Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein

Growing community of inventors

Rockville, MD, United States of America

Gwo-Yu Chuang